Cost and Access Barriers Are Changing How Americans Use GLP-1 Drugs
Millions of Americans are taking GLP-1 drugs in ways that differ from their prescribed use. Cost and access barriers are pushing some patients toward modified regimens, while others are using versions of the drugs that have not been approved for their treatment.
These practices reflect the difficulty many patients face in obtaining or affording GLP-1 medications as intended. They also highlight broader concerns about medical guidance, product quality, and oversight of unapproved weight-loss and diabetes treatments.